A Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2016
At a glance
- Drugs ABT 122 (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 24 Sep 2016 The trial has been completed in Germany (end date: 2016-08-02).
- 16 Jun 2016 Status changed from active, no longer recruiting to discontinued.
- 08 Jun 2016 This trial is discontinued in Czech Republic (end ate:2016-07-27) as per European Clinical Trials Database record.